23andMe returns as nonprofit with a 100 million-user target
Bloomberg reports the DNA-testing brand is returning as a nonprofit with a much bigger scale ambition.
By Ryan Merket ยท
Why it matters
23andMe's nonprofit turn tests whether a founder can rebuild trust in consumer genetics after bankruptcy, where the key asset is not a kit but users' willingness to share DNA data.
Bloomberg Technology reported that 23andMe is returning as a nonprofit with a goal of reaching 100 million users.
The move appears aimed at resetting the trust equation around one of consumer genetics' better-known names. Wikipedia currently describes 23andMe Research Institute as a Palo Alto-based nonprofit public benefit company in personal genomics and biotechnology.
The headline number is also the claim to watch. Bloomberg says 23andMe Research Institute is aiming for 100 million users, but the materials available for this story do not verify a current user count, financing plan, valuation, board structure, or the terms under which any existing data assets will be governed by the nonprofit.
The old product, in a different wrapper
The core 23andMe consumer proposition remains easy to understand: a customer submits a saliva sample, a lab analyzes the sample using single nucleotide polymorphism, or SNP, genotyping, and 23andMe generates reports about ancestry and genetic predispositions to some health-related conditions, according to Wikipedia.
That model depends on a bargain with users. 23andMe gets scale in genetic data and user relationships; users get personal reports and, potentially, the chance to contribute to research. A nonprofit structure could make that bargain easier to explain, but nonprofit status alone does not answer the hard questions: who governs the data, how consent is collected, how research access is priced or shared, and how long-term stewardship will be ensured.
Those details matter because 100 million users is not just a marketing target. In consumer genomics, a larger participant base can make a research platform more useful, but it also raises the stakes around security, consent, and the durability of the institution holding the data.
The strategic bet
The bet appears to be that a nonprofit can persuade many more people to share genetic information under a mission-driven structure.
The name 23andMe itself comes from the 23 pairs of chromosomes in a diploid human cell, according to Wikipedia. That origin story has always made 23andMe unusually personal for a technology brand. The product is not a workflow tool or a payments layer; it asks for biological material and returns information that can touch family, health, identity, and risk.
That is why the nonprofit relaunch should be judged less by the ambition of 100 million users than by the mechanics underneath it. A credible restart would need clear governance, plain-language consent, durable funding, and a reason for consumers to believe that 23andMe Research Institute can steward genetic data well as a nonprofit.
Bloomberg's report puts the ambition back on the table. The unanswered question is whether 23andMe Research Institute can convert that ambition into participation without asking users to take the governance model on faith.